Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $2.9B | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B | $3.8B | $2.9B | $2.8B | $2.3B | $2.1B | $2.1B | $2.2B | $2.2B | $2.1B | $1.9B | $1.7B | $1.6B | $2.0B | $1.8B | $1.5B |
| Bruttoergebnis | $1.5B | $1.5B | $1.3B | $1.3B | $1.8B | $2.3B | $2.0B | $1.3B | $1.3B | $1.0B | $972M | $930M | $971M | $940M | $924M | $824M | $740M | $699M | $835M | $715M | $623M |
| Bruttomarge % | 51.4% | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% | 44.8% | 45.0% | 45.6% | 46.0% | 44.2% | 43.4% | 43.4% | 43.7% | 42.9% | 43.4% | 45.1% | 42.6% | 40.0% | 40.3% |
| Betriebsergebnis (EBIT) | $360M | $357M | $411M | $399M | $781M | $1.3B | $1.0B | $405M | $371M | $305M | $306M | $267M | $230M | $259M | $201M | $118M | $173M | $140M | $201M | $175M | $152M |
| Operative Marge % | 12.4% | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 27.0% | 14.1% | 13.4% | 13.5% | 14.4% | 12.7% | 10.3% | 11.9% | 9.5% | 6.1% | 10.1% | 9.0% | 10.3% | 9.8% | 9.8% |
| Jahresüberschuss | $241M | $242M | $296M | ($118M) | $569M | $943M | $728M | $228M | $239M | $113M | $234M | $212M | $158M | $168M | $68M | $1M | $384M | $86M | $128M | $133M | $117M |
| Nettomarge % | 8.3% | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 5.0% | 11.1% | 10.1% | 7.1% | 7.8% | 3.2% | 0.1% | 22.5% | 5.5% | 6.6% | 7.4% | 7.6% |
| EBITDA | $773M | $663M | $840M | $714M | $1.2B | $1.6B | $1.2B | $515M | $505M | $446M | $386M | $352M | $323M | $332M | $223M | $200M | $267M | $201M | $263M | $245M | $229M |
| Ergebnis je Aktie (EPS) | $2.10 | $2.13 | $2.41 | $-0.95 | $4.50 | $8.08 | $6.50 | $2.04 | $2.14 | $1.02 | $2.12 | $1.87 | $1.39 | $1.48 | $0.60 | $0.01 | $3.25 | $0.73 | $1.08 | $1.10 | $0.93 |
| Ausstehende Aktien (Mio.) | 112M | 113M | 123M | 125M | 126M | 117M | 112M | 112M | 112M | 111M | 110M | 113M | 114M | 114M | 115M | 114M | 118M | 117M | 119M | 121M | 126M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für RVTY. /companies/us/RVTY
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms